期刊文献+

不同随访方式对房颤患者苄丙酮香豆素钠抗凝治疗的影响 被引量:1

The Influence of the Different Style of Follow-up Visit to the Anticoagulation Effect of Warfarin
下载PDF
导出
摘要 目的:探讨不同的随访方式对苄丙酮香豆素钠抗凝疗效的影响。方法:106例口服苄丙酮香豆素钠抗凝治疗的非瓣膜性房颤患者,随机分为专人负责的随访组和普通门诊的随访组,进行1年的治疗和观察,记录INR值和出血的发生情况。结果:与普通门诊的随访组相比,专人负责的随访组在开始治疗1个月时的达标率(92.3%)较普通门诊随访组(38.9%)明显增高,随访过程中稳定达标率(90.4%比33%)较高,发生出血和失访的情况较少,无患者自行停药,均具有显著差别。结论:专人负责的随访有利于提高苄丙酮香豆素钠的疗效。 Objective:To investigate the influence of the different style of follow-up visit to the anticoagulation effect of warfarin. Methods: 106 patients with nonvalvular atrial fibrillation who take orally warfarin for antithrombotic therapy randomized to special messenger in charge group and common clinic service group for follow-up, the value of INR, thromboembolic events and bleeding events were identified during follow-up of 1 year. Results: In the special messenger in charge group, the rate of qualification is higher after one month treatment of warfarin, and the rate kept stable during the 1-year follow-up. The incidence of bleeding events were lower, the patients lost to follow-up were less, no patient stopped medicine autonomously, The difference is significantly compared with those in the common clinical serve group. Conclusion:Special messenger in charge follow-up visit is profit to improve the effect of warfarin for antithrombolie therapy and decrease the side effect of bleeding at the same time.
出处 《中国临床医学》 北大核心 2008年第5期605-607,共3页 Chinese Journal of Clinical Medicine
关键词 非瓣膜性房颤 苄丙酮香豆素钠 抗凝治疗 Nonvalvular atrial fibrillation Warfarin Anticoagulative therapy
  • 相关文献

参考文献4

二级参考文献20

  • 1[1]Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications[J]. Clin Pharmacokinet, 2001,40(8):587. 被引量:1
  • 2[2]Tabrizi AR, Zehnbauer BA, Borecki IB,et al. The frequency and effects of cytochrome P450 (CYP)2C9 polymorphisms in patientsreceiving warfarin[J]. J Am Coll Surg, 2002,194(3):267~73. 被引量:1
  • 3[3]Daly AK, King BP. Pharmacogenetics of oral anticoagulants[J].Pharmacogenetics,2003, 13(5):247~52. 被引量:1
  • 4[4]Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily[J]. Br J Clin Pharmacol, 2001,52 (4):349~55. 被引量:1
  • 5[5]Gebauer MG,Nyfort-Hansen K,Henschke PJ,et al. Warfarin and acetaminophen interaction[J]. Pharmacotherapy,2003,23(1):109~12. 被引量:1
  • 6[6]Martin LA, Mehta SD. Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy[J]. Pharmacotherapy,2003,23(2):260~264. 被引量:1
  • 7[7]Jones CB, Fugate SE. Levofloxacin and warfarin interaction[J].Ann Pharmacother, 2002, 36 (10):1554~1557. 被引量:1
  • 8[8]Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin [J]. Pharmacol Ther, 1997,73(1):67~74. 被引量:1
  • 9[9]Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily [J]. Br J Clin Pharmacol, 2001,52 (4):349~355. 被引量:1
  • 10[10]Cambria JA. Effect of soy milk on warfarin efficacy[J]. Ann Pharmacother, 2002,36 (12):1893~1896. 被引量:1

共引文献507

同被引文献14

引证文献1

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部